Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy
Corinne Bousquet(Centre National de la Recherche Scientifique), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Mounira Chalabi(Université Toulouse III - Paul Sabatier), Charline Lasfargues(Inserm), Philippe Caron(Centre de Recherche en Cancérologie de Toulouse), Christiane Susini(Inserm), Siham Moatassim Billah(Inserm), Delphine Vezzosi(Centre de Recherche en Cancérologie de Toulouse)
Cited by 87
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284